Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/33037
Başlık: Investigation of new treatment option for hepatocellular carcinoma: A combination of sorafenib with usnic acid
Yazarlar: Yurdacan, Beste
Eskiler, Gamze Güney
Bursa Uludağ Üniversitesi/Tıp Fakültesi/Temel Tıp Bilimleri/Tıbbi Biyoloji Bölümü.
0000-0002-1619-6680
0000-0002-3820-424X
0000-0002-3316-316X
0000-0002-3316-316X
0000-0001-7904-883X
Egeli, Ünal
Eryılmaz, Işıl Ezgi
Çeçener, Gülşah
Tunca, Berrin
ABI-6078-2020
AAP-9988-2020
GWV-3548-2022
AAH-1656-2021
AAH-1420-2021
55665145000
57189380840
6508156530
6602965754
Anahtar kelimeler: Combination treatment
Hepatocellular carcinoma
Sorafenib
Usnic acid
Antitumor-activity
Cancer-cells
Inhibition
Pathway
Gene
P16
Pharmacology & pharmacy
Yayın Tarihi: Tem-2019
Yayıncı: Oxford University
Atıf: Yurdacan, B. vd. (2019). ''Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid''. Journal of Pharmacy and Pharmacology, 71(7), 1119-1132.
Özet: Objectives Sorafenib (SOR) is an orally administered molecular targeted agent in the systemic chemotherapy of hepatocellular carcinoma (HCC). However, the partial response of SOR is limited due to its adverse side effect and high heterogeneity and resistant phenotype of HCC. In the current study, we investigated synergistic effects of SOR and usnic acid (UA) on HCC cell lines including HepG2 and SNU-449, and a normal cell line, HUVEC. Methods The antiproliferative and apoptotic effects of combination therapy and SOR alone were analysed by WST-1 and Annexin V analysis, respectively. Furthermore, cell cycle, gene expression analysis of SOR-targeted kinases and acridine orange-ethidium bromide staining were also performed in combined treatments. Key findings Our results demonstrated that SOR and UA combination indicated a strong synergism in HCC cell lines and reduced SOR toxicity in HUVEC cells. Additionally, the combination treatment SOR and UA significantly induced much more apoptotic cell death and G0/G1 arrest through downregulation of SOR-targeted kinases. Conclusions Consequently, SOR and UA combination could be a new therapeutic strategy for HCC treatment.
URI: https://doi.org/10.1111/jphp.13097
https://academic.oup.com/jpp/article/71/7/1119/6122173
http://hdl.handle.net/11452/33037
ISSN: 0022-3573
2042-7158
Koleksiyonlarda Görünür:Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Egeli_vd_2019.pdf3 MBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons